Dennis has extensive experience across pharmaceuticals – retail and wholesale – and is currently the Executive Chairman and CEO of the Arrotex Australia Group of companies and Chairman at Juno Pharmaceuticals.
In 2015 Dennis, in partnership with Strides Pharmaceuticals, acquired the Arrow business from Aspen Pharmaceuticals for $350M. After buying out the Strides ownership in Arrow Pharmaceuticals in 2019, he merged the business with Apotex Australia to form Arrotex Pharmaceuticals. Prior to this, Dennis founded Ascent Pharmaceuticals in 2003 and as CEO went on to build a successful, Australian and Asian generic pharmaceutical company which was ultimately sold to Actavis Pharmaceuticals in 2012 for $400M.
Dennis was also the major shareholder and Chairman of the Central Healthcare group of companies which he developed in 2010 and which included CHS, a pharmacy wholesaling business, and PharmaSave, a retail pharmacy group. Dennis went on to sell the Central Healthcare group of companies to Sigma Pharmaceuticals in 2014.
Dennis is also currently the major shareholder and Chairman of myDNA – a world leading pharmacogenomic and health genomic platform technology.
LATEST NEWS: Dennis Bastas has recently announced his commitment to help Australia build its own sovereign manufacturing capability with the establishment of a Medicines Manufacturing & Development Future Fund to which Arrotex will commit assets and resources to ensure Australians have uninterrupted access to vital medicines in a time of crisis and which can also be utilised by Australian scientists to commercialise valuable Australian medical research and development projects.
Sandy’s career has seen him develop and manage consumer health brands, and consumer goods markets, in Australia, New Zealand, UK, USA, and more recently Europe. His 20+ years in the industry has provided Sandy with extensive experience in managing large multi-disciplinary teams, with multi-billion dollar portfolios, across a variety of market channels.
Sandy was the Regional Director for RB (ANZ) from 2015 – 2018, during which time he established a strong relationship with the Arrow and Apotex businesses, and many of our major pharmacy group customers. His work at RB in Australia has given him a strong insight into the challenges and opportunities of the Australian pharmacy sector and the branded consumer health market.
Andrew Burgess is a Chartered Accountant and has served alongside Dennis for more than 10 years, most recently as Arrow COO. Prior to this he played a pivotal role in the success of both Central Healthcare Services and Ascent Pharmaceuticals in the role of COO and CFO, respectively.
Sue began her legal career in the ABC Legal and Copyright Department. After being admitted to practice in 1999, she joined Herbert Geer and Rundle Lawyers and worked in the Media and Entertainment Group, acting for Village Roadshow, Austereo and the Mushroom Group. Sue moved into the pharmaceutical industry in 2007 when she joined Sigma Pharmaceuticals Limited as Corporate Counsel, moving into the position of General Counsel and Company Secretary in 2008. Sue left Sigma in 2015 to join Arrow Pharmaceuticals as GM Legal of the Arrow Group of Companies and is now Chief Legal Counsel of the Arrotex Group.